817 related articles for article (PubMed ID: 32476594)
21. Identification of naphthyridine and quinoline derivatives as potential Nsp16-Nsp10 inhibitors: a pharmacoinformatics study.
Aldahham BJM; Al-Khafaji K; Saleh MY; Abdelhakem AM; Alanazi AM; Islam MA
J Biomol Struct Dyn; 2022 Jun; 40(9):3899-3906. PubMed ID: 33252031
[TBL] [Abstract][Full Text] [Related]
22. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
[TBL] [Abstract][Full Text] [Related]
23. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
[TBL] [Abstract][Full Text] [Related]
24. A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19.
Perveen S; Khalili Yazdi A; Devkota K; Li F; Ghiabi P; Hajian T; Loppnau P; Bolotokova A; Vedadi M
SLAS Discov; 2021 Jun; 26(5):620-627. PubMed ID: 33423577
[TBL] [Abstract][Full Text] [Related]
25. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov.
Zhang H; Saravanan KM; Yang Y; Hossain MT; Li J; Ren X; Pan Y; Wei Y
Interdiscip Sci; 2020 Sep; 12(3):368-376. PubMed ID: 32488835
[TBL] [Abstract][Full Text] [Related]
26. Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin.
Krafcikova P; Silhan J; Nencka R; Boura E
Nat Commun; 2020 Jul; 11(1):3717. PubMed ID: 32709887
[TBL] [Abstract][Full Text] [Related]
27. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
[TBL] [Abstract][Full Text] [Related]
28. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.
Chakraborti S; Bheemireddy S; Srinivasan N
Mol Omics; 2020 Oct; 16(5):474-491. PubMed ID: 32696772
[TBL] [Abstract][Full Text] [Related]
29. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
30. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
[TBL] [Abstract][Full Text] [Related]
31. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.
Bhowmik D; Nandi R; Jagadeesan R; Kumar N; Prakash A; Kumar D
Infect Genet Evol; 2020 Oct; 84():104451. PubMed ID: 32640381
[TBL] [Abstract][Full Text] [Related]
32. Virtual Double-System Single-Box: A Nonequilibrium Alchemical Technique for Absolute Binding Free Energy Calculations: Application to Ligands of the SARS-CoV-2 Main Protease.
Macchiagodena M; Pagliai M; Karrenbrock M; Guarnieri G; Iannone F; Procacci P
J Chem Theory Comput; 2020 Nov; 16(11):7160-7172. PubMed ID: 33090785
[TBL] [Abstract][Full Text] [Related]
33. In silico molecular docking: Evaluation of coumarin based derivatives against SARS-CoV-2.
Chidambaram SK; Ali D; Alarifi S; Radhakrishnan S; Akbar I
J Infect Public Health; 2020 Nov; 13(11):1671-1677. PubMed ID: 33008777
[TBL] [Abstract][Full Text] [Related]
34. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel
Sencanski M; Perovic V; Pajovic SB; Adzic M; Paessler S; Glisic S
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842509
[TBL] [Abstract][Full Text] [Related]
35. High-resolution structures of the SARS-CoV-2 2'-
Rosas-Lemus M; Minasov G; Shuvalova L; Inniss NL; Kiryukhina O; Brunzelle J; Satchell KJF
Sci Signal; 2020 Sep; 13(651):. PubMed ID: 32994211
[TBL] [Abstract][Full Text] [Related]
36. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
Romeo A; Iacovelli F; Falconi M
Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126
[TBL] [Abstract][Full Text] [Related]
37. Biochemical screening for SARS-CoV-2 main protease inhibitors.
Coelho C; Gallo G; Campos CB; Hardy L; Würtele M
PLoS One; 2020; 15(10):e0240079. PubMed ID: 33022015
[TBL] [Abstract][Full Text] [Related]
38. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.
Encinar JA; Menendez JA
Viruses; 2020 May; 12(5):. PubMed ID: 32397643
[TBL] [Abstract][Full Text] [Related]
39. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
40. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
Hosseini FS; Amanlou M
Life Sci; 2020 Oct; 258():118205. PubMed ID: 32777300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
